Other Events ·
Johnson & Johnson announced a comprehensive resolution agreement for its remaining ovarian talc litigation…
JNJJohnson & Johnson
Johnson & Johnson announced a comprehensive resolution agreement for its remaining ovarian talc litigation, conditioned on at least 95% participation by claimants. The company committed $5.5 billion to settle these claims through per-claim payments, with the first tranche capped at $3 billion in 2027 and no further payments due before 2028. This settlement follows a favorable Multi-District Litigation court ruling on specific causation that undermined the plaintiffs' scientific evidence. Johnson & Johnson operates as a global healthcare company developing innovative medicines, medical devices, and consumer health products.